Nintedanib · Ofev, BIBF-1120

What is Nintedanib?

Nintedanib is a small-molecule inhibitor of multiple receptor tyrosine kinases including PDGFR, FGFR, VEGFR, and CSF1R. It binds competitively to the ATP binding pocket of these kinases and blocks intracellular signaling cascades involved in fibrotic tissue remodeling and angiogenesis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Ofev, BIBF-1120

Drug type

Small molecule

Targets

platelet-derived growth factor receptor alpha (PDGFRA), platelet-derived growth factor receptor beta (PDGFRB), fibroblast growth factor receptor 1 (FGFR1), fibroblast growth factor receptor 2 (FGFR2), fibroblast growth factor receptor 3 (FGFR3), vascular endothelial growth factor receptor 1 (FLT1)

Mechanism

Inhibitor of platelet-derived growth factor receptor alpha (PDGFRA), platelet-derived growth factor receptor beta (PDGFRB) and fibroblast growth factor receptor 1 (FGFR1)

Pathways

angiogenesis, fibrotic tissue remodeling

Therapy area

Oncology

Developer

Boehringer Ingelheim

In trials of

EOCN

FDA status

Approved as Ofev (October 15, 2014), NDA205832 · FDA label

UNII

G6HRD2P839

✅ FDA-approved uses

• Idiopathic pulmonary fibrosis
• Chronic fibrosing interstitial lung diseases with a progressive phenotype
• Systemic sclerosis-associated interstitial lung disease

From the indications section of the FDA label (version of Nov 20, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colorectal Cancer

Other drugs acting on PDGFRA / PDGFRB / FGFR1 / FGFR2 / FGFR3 / FLT1

Sources

• FDA label (DailyMed)
• FDA label Ofev (2025-11-20), indications
• NCI Thesaurus

Updated Oct 3, 2026.